Literature DB >> 11684961

Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer.

P S Kothari1, P T Scardino, M Ohori, M W Kattan, T M Wheeler.   

Abstract

Pelvic lymph node metastases in prostate cancer (PCa) carry an ominous prognosis. Periprostatic/periseminal vesicle (PP/PSV) lymph nodes are present in some individuals, but their incidence and involvement by metastases are unknown. A total of 832 of 1233 (67.5%) patients who underwent radical retropubic prostatectomy for clinically localized PCa at the Methodist Hospital from 1983 to 1998 by one surgeon (P.T.S.) had whole-mount slides available for review. Of these, 92 (11.1%) had received preoperative therapy (radiation in 48 [5.8%], hormonal in 44 [5.3%]). Slides were examined with the naked eye by placing them on a white illuminated background, and any area suggestive of a lymph node in PP/PSV fat was confirmed microscopically and assessed for the presence of metastases. Thirty-seven of 832 patients (4.4%) had 39 PP/PSV lymph nodes-one bilateral, one with two ipsilateral lymph nodes, and the rest solitary. Sizes ranged from 0.7 to 4.5 mm (mean 1.8 mm). Distribution was 2 of 39 (5.1%) apical, 3 of 39 (7.7%) mid, 17 of 39 (43.6%) base, and 17 of 39 (43.6%) seminal vesicle. Five patients (0.6%) had metastatic PCa to the PP/PSV lymph nodes. All five patients were of advanced pathologic T stage [one pT3a (extraprostatic extension) and four pT3b (seminal vesicle invasion)]. Only two of those five (40%) had metastases (all ipsilateral) to pelvic lymph nodes. In three of five (60%) the metastases were isolated to the PP/PSV lymph nodes. Metastases were to the lymph nodes in the periseminal vesicle fat in four of five (80%) of the cases and in the fat surrounding the base of the prostate in one of five (20%). Four of five (80%) patients recurred. Histologic grade (Gleason score), tumor volume, and failure (recurrence) rates were significantly different between the five patients with metastases and the 32 patients without metastases to the PP/PSV lymph nodes (p <0.0001, p <0.0001, and p = 0.005, respectively). However, there was no evidence that an individual patient's probability of having a PP/PSV lymph node increased with resection of the neurovascular bundle (p = 0.7698). PP/PSV lymph nodes are uncommon, but based upon these limited data, it appears that patients with metastases limited to PP/PSV lymph nodes have a poor prognosis (similar to pelvic lymph node metastases) and should be included in the American Joint Committee on Cancer (AJCC) Staging Manual to indicate "N1" if positive for metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11684961     DOI: 10.1097/00000478-200111000-00012

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

Review 1.  [Optimizing the use of radiotherapy with IMRT and image guided location of advanced prostate cancer].

Authors:  F Lohr; M Fuss; U Tiefenbacher; M Siegsmund; S Mai; J M Kunnappallil; B Dobler; P Alken; F Wenz
Journal:  Urologe A       Date:  2004-01       Impact factor: 0.639

Review 2.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

3.  Role of anterior prostatic fat pad dissection for extended lymphadenectomy in prostate cancer: a non-randomized study of 100 patients.

Authors:  Burak Ozkan; Burcin Tunc; Enis Rauf Coskuner; Yesim Saglican; Veli Yalçın
Journal:  Int Urol Nephrol       Date:  2015-04-22       Impact factor: 2.370

4.  The clinical features of anterior prostate cancers.

Authors:  Theresa M Koppie; Fernando J Bianco; Kentaro Kuroiwa; Victor E Reuter; Bertrand Guillonneau; James A Eastham; Peter T Scardino
Journal:  BJU Int       Date:  2006-10-09       Impact factor: 5.588

5.  Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.

Authors:  Kilian Schiller; K Sauter; S Dewes; M Eiber; T Maurer; J Gschwend; S E Combs; G Habl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-23       Impact factor: 9.236

6.  Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research.

Authors:  Srinivas Vourganti; Jeffrey Donaldson; Linda Johnson; Baris Turkbey; Gennady Bratslavsky; Leszek Kotula
Journal:  Exp Biol Med (Maywood)       Date:  2014-05-30

7.  Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer.

Authors:  Nilda González-Roibón; Jeong S Han; Stephen Lee; Zhaoyong Feng; Sehbal Arslankoz; Nathaniel Smith; Philip M Pierorazio; Elizabeth Humphreys; Theodore L Deweese; Alan W Partin; Trinity J Bivalacqua; Misop Han; Bruce Trock; Georges J Netto
Journal:  Int J Surg Pathol       Date:  2013-04-05       Impact factor: 1.271

8.  Robotic-assisted laparoscopic radical prostatectomy after aborted retropubic radical prostatectomy.

Authors:  Keith J Kowalczyk; Andy C Huang; Stephen B Williams; Hua-Yin Yu; Jim C Hu
Journal:  J Robot Surg       Date:  2012-08-19

Review 9.  Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation.

Authors:  Yu Xuan Kitzing; Adilson Prando; Celi Varol; Gregory S Karczmar; Fiona Maclean; Aytekin Oto
Journal:  Radiographics       Date:  2015-11-20       Impact factor: 5.333

10.  Oncologic outcomes in men with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institution international study.

Authors:  Young Suk Kwon; Yun-Sok Ha; Parth K Modi; Amirali Salmasi; Jaspreet S Parihar; Neal Patel; Izak Faiena; Michael May; David I Lee; Elton Llukani; Tuliao Patrick; Koon Ho Rha; Thomas Ahlering; Douglas Skarecky; Hanjong Ahn; Seung-Kwon Choi; Sejun Park; Seong Soo Jeon; Yen-Chuan Ou; Daniel Eun; Varsha Manucha; David Albala; Ketan Badani; Bertram Yuh; Nora Ruel; Tae-Hwan Kim; Tae Gyun Kwon; Daniel Marchalik; Jonathan Hwang; Wun-Jae Kim; Isaac Yi Kim
Journal:  BMC Urol       Date:  2015-08-01       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.